Clinical Trial Update: Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study using mesenchymal stem cells to treat refractory acute graft-versus-host disease; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Acute Graft-versus-host Disease | Phase 2 | Status: UNKNOWN